戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 f the angiotensin II type 1 receptor and the beta2 adrenoceptor.
2  than that in cells expressing the wild-type beta2-adrenoceptor.
3 ting G protein-coupled receptors such as the beta2-adrenoceptor.
4 wn and does not occur in the closely related beta2-adrenoceptor.
5 used beta-blockers are agonists at the human beta2-adrenoceptor.
6 and functional assays using human beta1- and beta2-adrenoceptors.
7 beta1-adrenoceptors and unlike those seen at beta2-adrenoceptors.
8 heir ability to internalize GFP-tagged human beta2-adrenoceptors.
9 (log KD -8.95) and is very selective for the beta2-adrenoceptor (1000-fold selectivity over the beta1
10 obodies) to directly probe activation of the beta2-adrenoceptor, a prototypical GPCR, and its cognate
11                                     Instead, beta2 adrenoceptor activation was responsible for mediat
12 n the amygdala is mediated by both beta1 and beta2-adrenoceptor activation.
13      We have further characterized the novel beta2 adrenoceptor agonist C26 (7-[(R)-2-((1R,2R)-2-benz
14 t dissociation rate we have observed for any beta2 adrenoceptor agonist tested to date.
15  who will inevitably be taking a long-acting beta2-adrenoceptor agonist (LABA)/ICS combination therap
16                                   Overuse of beta2-adrenoceptor agonist bronchodilators evokes recept
17 ubject to tachyphylaxis and would thus avoid beta2-adrenoceptor agonist resistance.
18            Bath application of the selective beta2-adrenoceptor agonist salmeterol (15 microM) facili
19                             In addition, the beta2-adrenoceptor agonist zinterol significantly increa
20 odimer combinations (with the Y4 receptor or beta2-adrenoceptor), agonist and antagonist pharmacology
21                                          The beta2 adrenoceptor agonists formoterol and salbutamol me
22 series of novel, potent, and selective human beta2 adrenoceptor agonists incorporating a sulfone moie
23 can be significantly enhanced by long-acting beta2-adrenoceptor agonists (LABAs) and may contribute t
24 opamine were as potent as several well-known beta2-adrenoceptor agonists (salbutamol, procaterol, and
25 ding kinetics of several clinically relevant beta2-adrenoceptor agonists and antagonists and demonstr
26 h drugs that are currently available such as beta2-adrenoceptor agonists and corticosteroids, it take
27 ent COPD therapy involving anticholinergics, beta2-adrenoceptor agonists and/or corticosteroids, do n
28 buterol has been one of the most widely used beta2-adrenoceptor agonists for the relief of the sympto
29  AHR in the neonatal exposure model, whereas beta2-adrenoceptor agonists had no such effect.
30 clic catecholamine surrogates present in the beta2-adrenoceptor agonists procaterol and BI-167107 (4)
31 tivation is attenuated following exposure to beta2-adrenoceptor agonists such as salbutamol, an effec
32       Dobutamine and terbutaline, beta1- and beta2-adrenoceptor agonists, evoked 17- and 5-fold incre
33                            Activation of the beta2-adrenoceptor and cannabinoid CB2 receptors can inh
34 r, was discovered much later than beta1- and beta2-adrenoceptors and exhibits unique properties which
35 lbutamol or by the addition of the selective beta2-adrenoceptor antagonist and inverse agonist ICI 11
36             In the presence of the selective beta2-adrenoceptor antagonist ICI 118,551 HCl (30 microM
37 t and that the administration of the beta1-, beta2-adrenoceptor antagonist propranolol decreases card
38  IBa was reversed by ICI-118,551, a specific beta2-adrenoceptor antagonist, but not by CGP 20712A, a
39 nce for a causal relationship between use of beta2-adrenoceptor antagonists and the increased risk of
40 dotoxin, nitro-L-arginine, guanethidine, and beta2-adrenoceptor antagonists.
41 n at least two active conformations, whereas beta2-adrenoceptors are able to induce signaling via dif
42 ssing human beta1, beta2, and chimeric beta1/beta2-adrenoceptors (ARs).
43 umulation and CRE gene transcription via the beta2-adrenoceptor at concentrations at which protein ki
44 ance of understanding the divergent roles of beta2-adrenoceptor (beta(2)AR) in high-fat diet-induced
45                                              beta2 adrenoceptor (beta2-AR)-agonists are used to relie
46                                     Anabolic beta2-adrenoceptor (beta2-AR) agonists have been propose
47                 In the heart, stimulation of beta2-adrenoceptor (beta2-AR), a prototypical GPCR, acti
48 echolamine synthesis/degradation and express beta2-adrenoceptors (beta2-AR).
49  of receptors and is implicated in switching beta2 adrenoceptor (beta2AR) G protein specificity in ca
50      Here we report a structure of the human beta2 adrenoceptor (beta2AR), which was crystallized in
51 lation sites into the C-terminal tail of the beta2-adrenoceptor (beta2AR) and demonstrate that this m
52 tion of high-affinity agonist binding at the beta2-adrenoceptor (beta2AR) expressed in Sf9 insect cel
53             In most studies, coupling of the beta2-adrenoceptor (beta2AR) to the stimulatory, heterot
54                                              beta2-Adrenoceptor (beta2AR)(-/-) FVB/NJ and wild-type F
55  that Vps34 is required for recycling of the beta2-adrenoceptor (beta2AR), a prototypical GPCR, and t
56 ists such as adrenaline, which activates the beta2-adrenoceptor (beta2AR), bind with relatively low a
57 ynamics simulations of lipid-embedded active beta2-adrenoceptor (beta2AR*) in complex with C-terminal
58                  (-)-CGP 12177, a beta1- and beta2-adrenoceptor blocker that causes agonist effects t
59     Labetalol, a combined alpha1, beta1, and beta2 adrenoceptor-blocking drug, has been shown to have
60 ct by reducing salmeterol's affinity for the beta2-adrenoceptor by 31-fold.
61 l signaling and highlight the ability of the beta2-adrenoceptor/cAMP/PKA axis to rewire EphA2 signali
62                                Prejunctional beta2-adrenoceptors can enhance neuronal acetylcholine r
63                  Some blockers of beta1- and beta2-adrenoceptors cause cardiostimulant effects throug
64  is currently thought that activation of the beta2-adrenoceptor causes c-AMP dependent activation of
65 cyclase activity in cells expressing the CAM beta2-adrenoceptor correlated well with the level of exp
66 axed preconstricted airways, irrespective of beta2-adrenoceptor desensitization.
67                                      The CAM beta2-adrenoceptor displayed higher affinity for the ago
68 s was not observed after exposure of the CAM beta2-adrenoceptor-expressing cells to alprenolol, and a
69 embrane (TM) regions of the human beta1- and beta2-adrenoceptors, followed by single point mutations,
70   In contrast, arrestin-3 interaction with a beta2-adrenoceptor fused to the carboxyl-terminal tail o
71   Functionally relevant polymorphisms of the beta2-adrenoceptor gene (ADRB2) are common in white popu
72 tution at the 16 position (rs1042713) in the beta2-adrenoceptor gene (ADRB2) is associated with enhan
73                                              Beta2-adrenoceptors, however, are proportionally higher
74 ding affinity for the human beta1 versus the beta2-adrenoceptor; however, the molecular/structural re
75 f C57BL/6J mice, pharmacologic activation of beta2 adrenoceptors improved the severity of shock, incl
76                  These results indicate that beta2-adrenoceptors in regulatory lymphocytes are critic
77 sponses to sustained stress are dependent on beta2-adrenoceptors in the CNS.
78 e potent compounds able to increase cAMP via beta2-adrenoceptors in U937 cells, and may have potentia
79 eoyldopamine were found to increase cAMP via beta2-adrenoceptors in U937 cells.
80  report evidence that agonist binding to the beta2 adrenoceptor induces a conformational change aroun
81 n of these amino acids to those found in the beta2-adrenoceptor (L195Q and W199Y), or mutation of a s
82       Despite the large up-regulation of CAM beta2-adrenoceptor levels, treatment with betaxolol did
83 ionship between structural properties of the beta2-adrenoceptor ligands and their interactions with m
84 orepinephrine, which then act on presynaptic beta2-adrenoceptors located on the neighboring nitrergic
85                        Here, measurements of beta2-adrenoceptor-mediated cAMP accumulation and cAMP r
86 1-adrenoceptor-mediated vasoconstriction and beta2-adrenoceptor-mediated vasodilation.
87 evealed an intense distribution of beta1-and beta2-adrenoceptor mRNA in the BLA.
88 t both systems converge in the activation of beta2-adrenoceptors of splenic regulatory lymphocytes to
89 ects via their binding to the active site of beta2-adrenoceptors on ASM, which triggers a signaling c
90 to express stably either the wild-type human beta2-adrenoceptor or a constitutively active mutant (CA
91  not demonstrate up-regulation of either CAM beta2-adrenoceptor or G(Salpha) mRNA, and up-regulation
92 O had no effect on signaling and function of beta2-adrenoceptor or numerous procontractile GPCRs, but
93 ptors, reduced homologous desensitization of beta2-adrenoceptors) or AMP-independent mechanisms (e.g.
94 sion levels of both beta-adrenoceptors, with beta2-adrenoceptors outnumbering beta1-adrenoceptors in
95              Here we show that activation of beta2-adrenoceptors promoted STD long-term synaptic pote
96 AMP-dependent (e.g., increased expression of beta2-adrenoceptors, reduced homologous desensitization
97           Bronchodilators that do not target beta2-adrenoceptors represent a critical unmet need for
98        Half-maximal up-regulation of the CAM beta2-adrenoceptor required concentrations of betaxolol
99 determine the exact amino acids in the human beta2-adrenoceptor responsible for this very high select
100 e protein LMBRD2 as a potential regulator of beta2 adrenoceptor signaling, underscoring the value of
101 ild-type mice selectively increased (40-60%) beta2-adrenoceptor signaling and function.
102 timulation mediated via canonical beta1- and beta2-adrenoceptor signaling pathways; and (5) evidence
103 ity to enforce the specificity of beta1- and beta2-adrenoceptor signaling.
104 ransregulation of M2 muscarinic receptors by beta2-adrenoceptor stimulation can be demonstrated at th
105           The pathway involves activation of beta2-adrenoceptors that increase cAMP levels and activa
106                           Desensitization of beta2-adrenoceptors that occurs during the first few day
107 y engineering phosphorylation sites into the beta2-adrenoceptor the receptor showed prolonged interac
108 y agonists induce a chemical modification in beta2-adrenoceptors (via phosphorylation) that reduces a
109  Betaxolol-mediated up-regulation of the CAM beta2-adrenoceptor was both time and concentration depen
110 en a phosphorylation-deficient mutant of the beta2-adrenoceptor was used.
111                           A series of mutant beta2 adrenoceptors with a limited number of cysteines a
112      Pretreatment of cells harboring the CAM beta2-adrenoceptor with betaxolol resulted in a large (4
113  growth factor receptor (EGFR) with EGF, the beta2-adrenoceptor with dopamine, or the hepatocyte grow
114                               Stimulation of beta2-adrenoceptors with the selective beta2 agonist pro

 
Page Top